Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

UroGen Pharma (URGN) Research & Development: 2015-2024

Historic Research & Development for UroGen Pharma (URGN) over the last 10 years, with Dec 2024 value amounting to $57.1 million.

  • UroGen Pharma's Research & Development rose 23.36% to $14.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $67.7 million, marking a year-over-year increase of 26.39%. This contributed to the annual value of $57.1 million for FY2024, which is 25.28% up from last year.
  • According to the latest figures from FY2024, UroGen Pharma's Research & Development is $57.1 million, which was up 25.28% from $45.6 million recorded in FY2023.
  • In the past 5 years, UroGen Pharma's Research & Development ranged from a high of $57.1 million in FY2024 and a low of $45.6 million during FY2023.
  • Moreover, its 3-year median value for Research & Development was $52.9 million (2022), whereas its average is $51.9 million.
  • In the last 5 years, UroGen Pharma's Research & Development dropped by 13.78% in 2023 and then grew by 25.28% in 2024.
  • Over the past 5 years, UroGen Pharma's Research & Development (Yearly) stood at $47.3 million in 2020, then increased by 0.70% to $47.6 million in 2021, then rose by 11.05% to $52.9 million in 2022, then fell by 13.78% to $45.6 million in 2023, then grew by 25.28% to $57.1 million in 2024.